Ionis Pharmaceuticals (IONS) EBITDA Margin (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly EBITDA Margin of 38.18% for Q2 2026, down 6911.0% year-over-year from 0.56% in Q2 2025, and up 83.74% quarter-over-quarter from 234.85% in Q1 2026.
Powered by 
Analysis
Ionis Pharmaceuticals (IONS) EBITDA Margin (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' EBITDA Margin history runs 18 years deep, the most recent figure standing at 38.18% for Q2 2026.
- In Q2 2026, EBITDA Margin fell 6911.0% year-over-year to 38.18%; the TTM figure through Jun 2026 stood at 87.66% (down 5943.0% YoY), while the FY2025 annual figure was 40.45%, up 2693.0% from the prior year.
- EBITDA Margin for Q2 2026 stood at 38.18%, up from 234.85% in the prior quarter.
- The five-year high for EBITDA Margin was 30.93% in Q2 2025, with the low at 234.85% in Q1 2026.
- The 5-year median for EBITDA Margin is 75.68% (2023), against an average of 77.27%.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin tumbled 18709 bps in 2022, then jumped 13507 bps in 2023.
- Ionis Pharmaceuticals' EBITDA Margin stood at 136.95% in 2022, then surged by 99 bps to 1.89% in 2023, then plunged by 2493 bps to 48.91% in 2024, then sank by 116 bps to 105.47% in 2025, then surged by 64 bps to 38.18% in 2026.
- Business Quant data shows IONS's EBITDA Margin at 38.18% in Q2 2026, 234.85% in Q1 2026, and 105.47% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Ionis Pharmaceuticals | 9.60 Bn | 7.55 Bn | 265.21 Mn | -38.18% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -38.18% |
| Mar 31, 2026 | -47.72% |
| Dec 31, 2025 | -105.47% |
| Sep 30, 2025 | -102.21% |
| Jun 30, 2025 | 30.93% |
| Mar 31, 2025 | -111.59% |
| Dec 31, 2024 | -48.91% |
| Sep 30, 2024 | -111.09% |
| Jun 30, 2024 | -29.34% |
| Mar 31, 2024 | -125.12% |
| Dec 31, 2023 | -1.89% |
| Sep 30, 2023 | -99.35% |
| Jun 30, 2023 | -47.87% |
| Mar 31, 2023 | -87.45% |
| Dec 31, 2022 | -136.95% |
| Sep 30, 2022 | -37.03% |
| Jun 30, 2022 | -63.92% |
| Mar 31, 2022 | -40.52% |
| Dec 31, 2021 | 50.14% |
| Sep 30, 2021 | -64.50% |